MXPA03001226A - Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados. - Google Patents

Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.

Info

Publication number
MXPA03001226A
MXPA03001226A MXPA03001226A MXPA03001226A MXPA03001226A MX PA03001226 A MXPA03001226 A MX PA03001226A MX PA03001226 A MXPA03001226 A MX PA03001226A MX PA03001226 A MXPA03001226 A MX PA03001226A MX PA03001226 A MXPA03001226 A MX PA03001226A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
related methods
cell death
pyrimidinamine derivatives
derivatives
Prior art date
Application number
MXPA03001226A
Other languages
English (en)
Inventor
Malcolm Scott
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA03001226A publication Critical patent/MXPA03001226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Esta invencion proporciona derivados novedosos neuroprotectores de la 4-pirimidinamina, y composiciones farmaceuticas neuroprotectoras que comprenden 4-pirimidinaminas. Esta invencion proporciona tambien metodos de uso de estas composiciones para evitar la muerte celular isquemica, particularmente muerte neuronal de celulas, y reducir la probabilidad de muerte celular neuronal en un sujeto debido a un evento traumatico. Finalmente, esta invencion proporciona un aparato para administrar a un sujeto las composiciones farmaceuticas actuales.
MXPA03001226A 2000-08-08 2001-08-06 Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados. MXPA03001226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379100P 2000-08-08 2000-08-08
PCT/US2001/024659 WO2002012198A2 (en) 2000-08-08 2001-08-06 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
MXPA03001226A true MXPA03001226A (es) 2004-09-10

Family

ID=22837982

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001226A MXPA03001226A (es) 2000-08-08 2001-08-06 Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.

Country Status (16)

Country Link
US (3) US20030008883A1 (es)
EP (1) EP1313713B1 (es)
JP (1) JP2004505952A (es)
CN (1) CN1468225A (es)
AR (1) AR031601A1 (es)
AT (1) ATE398109T1 (es)
AU (1) AU2001281120A1 (es)
BR (1) BR0113165A (es)
CA (1) CA2419030A1 (es)
DE (1) DE60134414D1 (es)
HK (1) HK1054033A1 (es)
IL (1) IL154240A0 (es)
MX (1) MXPA03001226A (es)
NZ (1) NZ524100A (es)
WO (1) WO2002012198A2 (es)
ZA (1) ZA200301868B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2005009977A1 (en) * 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
CA2533397A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
JP2007512275A (ja) * 2003-11-24 2007-05-17 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾリルおよびイミダゾリルピリミジン
US7534798B2 (en) * 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP5097539B2 (ja) * 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド タンパク質キナーゼ調節剤および使用方法
AU2005256659A1 (en) 2004-06-28 2006-01-05 Nycomed Gmbh 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
WO2006047492A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
JP5733839B2 (ja) * 2010-03-26 2015-06-10 国立大学法人北海道大学 神経変性疾患治療薬
NZ705313A (en) * 2012-08-23 2018-03-23 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives
RS57662B1 (sr) * 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
BR112020007549A2 (pt) * 2017-10-17 2020-09-24 Merck Patent Gmbh compostos inibidores de pirimidina tbk/ikképsilon e uso dos mesmos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068271A (en) * 1988-09-21 1991-11-26 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines compositions
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
PL313973A1 (en) * 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
CN1198613C (zh) * 1998-10-16 2005-04-27 第一三得利制药株式会社 氨基苯氧基乙酸衍生物和含有它们的药用组合物
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体

Also Published As

Publication number Publication date
ZA200301868B (en) 2004-06-25
EP1313713A2 (en) 2003-05-28
EP1313713B1 (en) 2008-06-11
AU2001281120A1 (en) 2002-02-18
WO2002012198A2 (en) 2002-02-14
BR0113165A (pt) 2003-07-15
US20040006094A1 (en) 2004-01-08
US20030212079A1 (en) 2003-11-13
ATE398109T1 (de) 2008-07-15
CA2419030A1 (en) 2002-02-14
NZ524100A (en) 2005-01-28
CN1468225A (zh) 2004-01-14
DE60134414D1 (de) 2008-07-24
US20030008883A1 (en) 2003-01-09
JP2004505952A (ja) 2004-02-26
IL154240A0 (en) 2003-07-31
WO2002012198A3 (en) 2002-06-06
AR031601A1 (es) 2003-09-24
HK1054033A1 (zh) 2003-11-14

Similar Documents

Publication Publication Date Title
MY125978A (en) Admantane derivatives
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
MY135683A (en) Compositions for improving fertility
BE2013C064I2 (es)
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
IL139227A0 (en) N-substituted aminotetralins as ligands for the neuropeptide yy5 receptor useful in the treatment of obesity and other disorders
MXPA03001226A (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
EP1391200A4 (en) DRUG
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
GB0002336D0 (en) Medicaments
IL154096A0 (en) Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MXPA02001631A (es) Composiciones farmaceuticas para administracion oral y topica.
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
IL166596A0 (en) Salt of morphine-6-glucoronide
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
HUP0500958A3 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
HK1052168A1 (en) N-deacetylthiocolchincine derivatives and pharmaceutical compositions containing them.
AP9200443A0 (en) Heterocyclic compounds.
GB0128071D0 (en) Medicament

Legal Events

Date Code Title Description
FG Grant or registration